Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19

The respiratory tract represents the key target for antiviral delivery in early interventions to prevent severe COVID‐19. While neutralizing monoclonal antibodies (mAb) possess considerable efficacy, their current reliance on parenteral dosing necessitates very large doses and places a substantial b...

Descripción completa

Detalles Bibliográficos
Autores principales: McSweeney, Morgan D., Stewart, Ian, Richardson, Zach, Kang, Hyunah, Park, Yoona, Kim, Cheolmin, Tiruthani, Karthik, Wolf, Whitney, Schaefer, Alison, Kumar, Priya, Aurora, Harendra, Hutchins, Jeff, Cho, Jong Moon, Hickey, Anthony J., Lee, Soo Young, Lai, Samuel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537933/
https://www.ncbi.nlm.nih.gov/pubmed/36248234
http://dx.doi.org/10.1002/btm2.10391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537933/
https://www.ncbi.nlm.nih.gov/pubmed/36248234
http://dx.doi.org/10.1002/btm2.10391

Ejemplares similares